877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

D3 antagonists

Categories

Antipsychotics (4)
Aromatic compounds (4)
Cyclic compounds (4)
D2 antagonists (4)
Dopamine antagonists (4)
Drugs acting on the nervous system (4)
Pharmaceuticals (4)
Psychoactive drugs (4)
Psychopharmacology (4)
Drugs acting on the cardiovascular system (3)
Fluoroarenes (3)
Six-membered rings (3)
Alpha blockers (2)
Alpha-1 blockers (2)
Alpha-2 blockers (2)
Antihypertensive agents (2)
Atypical antipsychotics (2)
D4 antagonists (2)
Drugs acting on the genito-urinary system (2)
Drugs for benign prostatic hyperplasia (2)
Piperazines (2)
Typical antipsychotics (2)
Urologicals (2)
Antiarrhythmic agents (1)
Antidepressants (1)
Antihistamines (1)
Antiparkinsonian agents (1)
Chloroarenes (1)
D2-receptor agonists (1)
D3 receptor agonists (1)
Diphenylbutylpiperidines (1)
Dopamine agonists (1)
H1 receptor antagonists (1)
Mood stabilizers (1)
Piperidines (1)
Potassium channel blockers (1)
Psychoanaleptics (1)
Ureas (1)

Suppliers

Sigma Aldrich (4)
AK Scientific (2)
TCI Chemicals (2)
Accela (1)
Matrix Scientific (1)
Toronto Research Chemicals (1)

Aripiprazole (129722-12-9)  
Aripiprazole, sold under the brand name Abilify among others, is an atypical antipsychotic. From April 2013 to March 2014, sales of Abilify amounted to almost $6.9 billion.. It is recommended by some doctors and used in the treatment of schizophrenia and bipolar disorder.
pimozide (2062-78-4)  
Orap  ·  Antalon  ·  Orap forte
Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1).
Pipamperone (1893-33-0)  
R 3345  ·  Dipiperon  ·  1'-(3-(4-fluorobenzoyl)propyl)-(1,4'-bipiperidine) -4'-carboxamide
Pipamperone (INN, USAN, BAN), also known as carpiperone and floropipamide or fluoropipamide, and as floropipamide hydrochloride (JAN), is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia. It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan. Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.
Blonanserin (132810-10-7)  
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.